Protagonist Therapeutics (PTGX) News Today $51.07 +0.11 (+0.22%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$50.60 -0.48 (-0.93%) As of 08/8/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Wedbush Expects Higher Earnings for Protagonist TherapeuticsAugust 9 at 11:44 AM | marketbeat.com7PTGX : What 4 Analyst Ratings Have To Say About Protagonist...August 8 at 12:14 PM | benzinga.comJMP Securities Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) StockAugust 8 at 9:55 AM | marketbeat.comProtagonist Therapeutics files automatic mixed securities shelfAugust 7 at 5:08 AM | msn.comProtagonist (PTGX) Q2 Revenue Falls 26%August 7 at 2:00 AM | fool.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Raised by XTX Topco LtdAugust 5, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Buy" by AnalystsAugust 4, 2025 | marketbeat.comJupiter Asset Management Ltd. Makes New $8.13 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)August 4, 2025 | marketbeat.comGSA Capital Partners LLP Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)August 4, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Holdings Raised by Envestnet Asset Management Inc.August 4, 2025 | marketbeat.comJefferies Financial Group Inc. Sells 857,602 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)August 1, 2025 | marketbeat.comProtagonist Therapeutics (PTGX) Expected to Announce Quarterly Earnings on TuesdayJuly 30, 2025 | marketbeat.comRoyce & Associates LP Makes New $593,000 Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 30, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells $570,533.70 in StockJuly 29, 2025 | marketbeat.comInsider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells 10,415 Shares of StockJuly 29, 2025 | insidertrades.comSkandinaviska Enskilda Banken AB publ Sells 61,700 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 27, 2025 | marketbeat.comVictory Capital Management Inc. Sells 138,406 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 27, 2025 | marketbeat.comY Intercept Hong Kong Ltd Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 26, 2025 | marketbeat.comInsider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells 12,859 Shares of StockJuly 24, 2025 | marketbeat.comDinesh V. Ph D. Patel Sells 17,520 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) StockJuly 24, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells $1,214,678.25 in StockJuly 24, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Trading Down 4.8% - Time to Sell?July 24, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells $705,444.74 in StockJuly 24, 2025 | insidertrades.comBurney Co. Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 23, 2025 | marketbeat.comJennison Associates LLC Buys Shares of 18,317 Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 22, 2025 | marketbeat.comBank of New York Mellon Corp Reduces Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 19, 2025 | marketbeat.comHussman Strategic Advisors Inc. Has $2.54 Million Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 18, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Increased by Principal Financial Group Inc.July 12, 2025 | marketbeat.comChina Universal Asset Management Co. Ltd. Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 9, 2025 | marketbeat.comNew York State Teachers Retirement System Has $2.27 Million Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 9, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by AnalystsJuly 9, 2025 | marketbeat.comTrek Financial LLC Invests $2.83 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 8, 2025 | marketbeat.comMoody Aldrich Partners LLC Boosts Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 4, 2025 | marketbeat.comIllinois Municipal Retirement Fund Reduces Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 2, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Trading Down 7.2% - What's Next?July 1, 2025 | marketbeat.comProtagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for ObesityJune 30, 2025 | usatoday.comCan Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?June 30, 2025 | msn.comPTGX Protagonist Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comProtagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia VeraJune 24, 2025 | msn.comProtagonist Therapeutics’ SWOT analysis: biotech stock poised for growthJune 20, 2025 | investing.comCiti Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs OpportunityJune 20, 2025 | msn.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Position Lifted by Exchange Traded Concepts LLCJune 19, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Now Covered by CitigroupJune 17, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 7,367 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 17, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Buy" from BrokeragesJune 14, 2025 | marketbeat.comGAMMA Investing LLC Raises Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 13, 2025 | marketbeat.comArturo Md Molina Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) StockJune 12, 2025 | insidertrades.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Arturo Md Molina Sells 10,000 SharesJune 11, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Hold" at Wall Street ZenJune 8, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Sells 6,008 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 7, 2025 | marketbeat.com Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address PTGX Media Mentions By Week PTGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTGX News Sentiment▼0.690.50▲Average Medical News Sentiment PTGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTGX Articles This Week▼146▲PTGX Articles Average Week Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dr. Reddy's Laboratories News Qiagen News Moderna News Ascendis Pharma A/S News Viatris News BridgeBio Pharma News Verona Pharma PLC American Depositary Share News Blueprint Medicines News Roivant Sciences News Grifols News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTGX) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
